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Abstract: In recent years, a number of studies have examined tools to identify elderly patients who 
are at increased risk of drug-related problems (DRPs). There has been interest in developing tools 
to prioritise patients for clinical pharmacist (CP) review. This systematic review (SR) aimed to 
identify published primary research in this area and critically evaluate the quality of prediction tools 
to identify elderly patients at increased risk of DRPs and/or likely to need CP intervention. The 
PubMed, EMBASE, OVID HMIC, Cochrane Library, PsychInfo, CINAHL PLUS, Web of Science and 
ProQuest databases were searched. Keeping up to date with research and citations, the reference 
lists of included articles were also searched to identify relevant studies. The studies involved the 
development, utilisation and/or validation of a prediction tool. The protocol for this SR, 
CRD42019115673, was registered on PROSPERO. Data were extracted and systematically assessed 
for quality by considering the four key stages involved in accurate risk prediction models—
development, validation, impact and implementation—and following the Checklist for the critical 
Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS). 
Nineteen studies met the inclusion criteria. Variations in study design, participant characteristics 
and outcomes made meta-analysis unsuitable. The tools varied in complexity. Most studies reported 
the sensitivity, specificity and/or discriminatory ability of the tool. Only four studies included 
external validation of the tool(s), namely of the BADRI model and the GerontoNet ADR Risk Score. 
The BADRI score demonstrated acceptable goodness of fit and good discrimination performance, 
whilst the GerontoNet ADR Risk Score showed poor reliability in external validation. None of the 
models met the four key stages required to create a quality risk prediction model. Further research 
is needed to either refine the tools developed to date or develop new ones that have good 
performance and have been externally validated before considering the potential impact and 
implementation of such tools. 
Keywords: clinical pharmacy; risk assessment tools; frail elderly; hospital care 
 
1. Introduction 
A drug-related problem (DRP) has been defined as ‘an event or circumstance involving drug 
therapy that actually or potentially interferes with the desired health outcome’ [1]. DRPs can cause 
serious harm, hospital admissions, increased health care costs and even death and are known to be 
prevalent in elderly patients both in the community and in the hospital setting [2]. DRPs include 
medication errors, adverse drug reactions (ADRs), and adverse drug events (ADEs) [3]. Elderly (or 
older) people, defined as those aged 65 years and over [4,5] with multiple co-morbidities receiving 
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multiple medicines for management/treatment of long-term illness are prone to adverse drug 
reactions and are likely to be more susceptible to adverse drug events in general [2]. The “oldest-old” 
are a subgroup of elderly people, defined by the WHO as those aged 80 years and older [5]. The 
reported percentages of ADRs for all hospitalized patients vary between 2.4% and 10.9% [6], with a 
higher incidence of ADRs in older people, as they are prescribed significantly more drugs than 
younger individuals, and older people are nearly seven-times more likely to be hospitalized due to 
an ADR compared to younger people [6,7]. A number of studies have aimed to determine the risk 
factors associated with ADEs, ADRs and/or DRPs which may help to identify patients at risk of such 
events and prioritise these (high risk) patients for intervention [7,8]. The authors of a previous 
systematic review (SR) concluded that failure to consider risk prediction in a clinical setting can result 
in poor care and many guidelines have recommended incorporating life expectancy into clinical 
decisions to help target services to those who might benefit the most [9], such as in decisions to 
discontinue breast, colon and prostate cancer screening based on age and life expectancy [10–12]. 
A simplistic definition of inappropriate prescribing is that it is “The practice of administering 
medications in a manner that poses more risk than benefit, particularly where safer alternatives  
exist” [13]. Inappropriate prescribing encompasses potentially inappropriate medications (PIMs) 
(misprescribing and overprescribing) and potential prescribing omissions (PPOs) or 
underprescribing [14,15]. Inappropriate prescribing is highly associated with an increased risk of 
adverse drug events especially in older patients with poly pharmacy who are more vulnerable [15]. 
In their review of inappropriate prescribing, O’Connor et al. commented that “given the complexity 
of prescribing decisions in the elderly a more holistic definition of inappropriate prescribing should 
encompass the assessment of older persons’ prescription medications in the context of their multiple 
co-morbidities, complex medication regimes, functional and cognitive status, treatment goals and life 
expectancy”[14]. Whilst not exclusive to the elderly, the prescribing of potentially inappropriate 
medications to older people has been shown to be highly prevalent, with rates ranging from 12% for 
community-dwelling elderly to 40% in nursing home residents [16]. Inappropriate prescribing is 
associated with adverse drug events [16]. A number of tools have been developed to measure and 
assess medication appropriateness in older people which can be measured and assessed by using, for 
example, the Medication Appropriateness Index (MAI). In addition, inappropriate prescribing 
criteria sets such as the STOPP/START criteria can be applied to medication lists. However, these 
tools can be time consuming to utilise, which currently limits their use in routine clinical practice [17]. 
It is well recognised both within Europe and internationally that there is a need to prioritise 
pharmaceutical care [18,19]. Hospital clinical pharmacists are a limited and expensive resource, 
making routine screening of all Emergency Department patients by pharmacists unsustainable [20]. 
Within the National Health Service (NHS) in the United Kingdom, it is recognised that “Clinical 
pharmacists cannot review all patients every day”[19] and that “to allocate clinical pharmacist 
resource where it is most needed, patients’ pharmaceutical care needs must be assessed and 
prioritised accordingly”[19]. In America, a $0.5 million research grant was awarded by the American 
Society of Health-System Pharmacists to develop and validate a pharmaceutical complexity scoring 
tool [18]. Pharmacists cannot identify and manage all drug-related problems but need to prioritise 
and “identify those drug-related problems for which management or prevention would result in the 
greatest benefit for as many patients as possible” [21]. In a recently published article looking at 
prioritising pharmaceutical care, the authors commented that there is an “urgent need for pharmacy 
departments to prioritise which patients need direct pharmaceutical care on a daily basis” [18]. 
There is limited published literature about the current imperfect use of pharmaceutical care 
priority screening tools in UK hospitals [18]. In recent years, a number of researchers have looked at 
identifying risk factors for drug-related problems (DRPs) and developing screening and acuity tools 
to help prioritise clinical pharmacist workflow, and research continues to develop such tools both in 
the UK and abroad [18,22]. A SR published in 2016 found 38 studies (that met their inclusion criteria) 
that identified measurable risk factors associated with adult hospital inpatients that potentially lead 
to a pharmaceutical intervention [23]. Stevenson et al. conducted a SR of risk prediction models used 
to predict ADRs in older adults [7]. They included studies that developed and validated an ADR 
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prediction model for use in patients over 65 years old, using a multivariable approach in the design 
and analysis; only four studies met the inclusion criteria for the SR, emphasising the deficit in 
published research on this topic in this subgroup of patients (hospital inpatients aged over 65 years) 
[7]. Stevenson et al.’s SR included only four studies, and additional studies have been published since 
2014. Furthermore, a quality assessment of studies could not be generated in Stevenson et al. [7]. This 
paucity of evidence was the driver to carry out a systematic review of the literature to (1) identify any 
existing primary research that involves the development and/or utilisation and/or validation of a 
prediction tool or risk score system to identify those patients most likely to experience DRPs and/or 
benefit from hospital pharmacist intervention, and (2) critically evaluate the quality of the identified 
research. In particular, this SR aimed to identify and focus on any research that includes or is specific 
to elderly patients (aged over 65 years old). 
2. Materials and Methods  
2.1. Data Resources 
A systematic search of research articles published in peer-reviewed health care-related journals 
was performed. The following databases were searched from inception until April–May 2018 with 
no date restrictions applied: PubMed, Embase, OVID HMIC, Cochrane Library, Psychinfo, CINAHL 
PLUS, Web of Science, and ProQuest.  
These databases were selected based on previous SRs conducted by pharmacist researchers with 
similar aims. The titles of all papers (n=1030) were screened and, if the title suggested that the paper 
might be relevant to the topic (prediction tools and/or risk factors for DRPs), the abstracts (where 
available from search databases) were reviewed by the principal researcher (AB). Following this 
review of titles and abstracts, full-text publications were accessed for all potentially relevant papers 
and evaluated through intensive reading by the principal researcher. Details of all sourced full-text 
articles were tabulated to allow validation of a final list of citations and for a final list of included 
papers to be drawn up. Details of any articles for which there were queries were also tabulated and 
were referred to two independent reviewers (CC and ZJ). The reviewers considered the queries 
separately and then the three researchers discussed each individual query paper and reached 
consensus on whether it should be included in the SR. From the search of the eight databases, eight 
papers were identified that met the inclusion criteria. 
A number of additional papers (11 further papers) were identified for inclusion in this SR (these 
papers were found in the initial scoping search and in the databases, and duplicates were removed). 
An internet search using the search engine Google Scholar was used as part of a scoping exercise 
when the principal researcher was initially considering conducting research in this area in order to 
gauge the amount of published research on this topic. From this search, a relevant systematic review 
published in 2014 was identified assessing the use of risk prediction models to predict adverse drug 
reactions in older people [7]. The systematic review (which was not itself included in this SR, as it did 
not meet the inclusion criteria) identified four relevant papers; these four papers were sourced and 
reviewed to determine whether they were relevant for inclusion in this systematic review.  
An additional paper was also identified whilst trying to locate the full-text article of one of the 
papers included in the aforementioned SR, namely a paper by Tangiisuran B.[24], which led to the 
identification of another paper by Tangiisuran B. et al.[25] reporting the same research, namely the 
BADRI risk prediction model; these two papers describe the same research and have been considered 
as a single piece of research in this SR. 
Another four papers were identified having been referenced or mentioned in one of the 8 papers 
from the search of the medical databases. Three further papers were identified through keeping up 
to date with research publications and from a review of relevant conference proceedings. 
A total of 19 papers were identified and included in the SR through the systematic search of 
eight medical databases and other methods described as summarised in Figure 1. 
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2.2. Data Extraction 
Results were extracted and tabulated according to the papers included in the SR, population 
characteristics, sample size, study setting, whether the study examined at development, utilisation 
and/or validation of prediction tool, study outcomes, risk tools and performance of risk tools. 
2.3. Search Terms and Search Strategy 
PICOS is a framework designed to make the process of defining and designing a research 
question easier, where PICOS stands for: P Population/Patient, I Intervention, C Comparison, O 
Outcome, and S Study Design [26]. The author referred to the principles of the PICOS method to 
formulate a search strategy and select keywords relevant to the current research.  
In view of the structural and content-related differences between the databases, particularly 
between the indexing and thesauri/controlled vocabulary used by PubMed (Medical Subject 
Headings, MeSH) and EMBASE (Emtree) a number of different search terms and combinations of 
terms were used. A combination of MeSH/Emtree and free-text search terms were used. The search 
terms included synonyms and various combinations of the following keywords “elderly”, 
“pharmacist”, “hospital”, “risk”, “risk factor” and “risk assessment,” with the combinations used 
reflecting the specific search capabilities of the different databases. For example, for those databases 
identifying a comparatively large number of articles from a search using the terms “elderly”, 
“pharmacist” and “hospital”, additional terms relating to risk were added to narrow the search to 
focus upon more relevant articles. Keywords not listed as MeSH or Map Terms were searched as 
phrases using the free-text search mode. A further list of search terms was generated by referring to 
a previous review with similar aims [7]. The reference list of relevant papers was also searched in 
order to identify any additional studies. Duplicate articles were removed if they were found in the 
different databases.  
The search strategy appears in File S1, PubMed search strategy. This was supported by use of a 
checklist File S2 PRISMA 2009 checklist to ensure that PRISMA principles were followed during the 
process. 
The following combination of search terms was used when conducting the scoping exercise 
(already described) on Google Scholar: +risk tool +elderly +drug-related problems.  
Figure 1 summarises the number of potentially relevant papers that were identified and the final 
number included in the SR, based on (a simplified version of) the PRISMA flow diagram. 
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Figure 1. PRISMA flow diagram. 
2.4. Inclusion and Exclusion Criteria 
2.4.1. Paper Inclusion Criteria 
Inclusion criteria for the SR included studies published in the English language, primary 
research/studies including (but not exclusively) patients aged 65 years and over, inpatients in 
secondary or tertiary care centres (hospitals), medically admitted patients, where interventions take 
place in the hospital setting, all primary research and research for which the full-text article was 
available for review. 
2.4.2. Paper Exclusion Criteria 
Exclusion criteria for the SR included systematic reviews; literature reviews; meta-analyses; 
summary articles; discussion articles; conference proceedings; editorials; surgically admitted 
patients; studies solely in patients in specialist care settings, e.g., intensive care or psychiatry (but not 
geriatric/older persons wards); studies looking at specific areas, e.g., blood glucose or HbA1c control 
or dementia; studies conducted in community pharmacy, primary care settings, outpatients or 
attending outpatient clinics (e.g., diabetes, heart failure clinics), those in ambulatory care and patients 
(solely) aged <65 years; studies where one or more of the interventions took place in the 
home/community setting; studies that focussed solely on interventions at the point of or following 
hospital discharge/transition. The SR excluded proposals for research (e.g., published research 
protocols) for which results had not been published (in journals included in the selected 
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databases)/were not available through the databases used and research where only the abstract was 
available for review. In addition, studies using a set of arbitrary or predetermined factors 
incorporated in a tool/scoring system that were not developed or tested with any statistical analysis 
methods (such as regression analysis) to determine relevance of the variables were excluded. 
2.4.3. Critical Appraisal and Data Extraction for Included Studies 
The studies identified via the searches were initially reviewed by the principal researcher 
considering the four key stages involved in accurate risk prediction models—development, 
validation, impact and implementation—as described by Petrovic M. [27]. To assess the bias and 
quality of the included studies in a systematic manner, the Checklist for the critical Appraisal and 
data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) was used by the 
principal researcher to critically appraise the studies. The items extracted using the checklist were 
then tabulated into Excel spreadsheets—the format of which was influenced by the tabulated results 
included in a recently published systematic review relevant to this topic by Falconer N. et al. [28].  
The protocol for this SR, CRD42019115673, was registered on PROSPERO [29]. 
3. Results 
Nineteen papers were included in the SR, and the citations are included in Table 1. 
Table 1. Table showing the papers included in this systematic review (SR). 
Author Tool 
Tangiisuran B. et al. [25] (note: this research 
was also reported in PhD thesis [24] but only 
counted as one piece of research in this SR) 
BADRI model 
Onder G. et al. [30] GerontoNet ADR Risk Score 
Trivalle C. et al. [31] A geriatric score 
O’Connor M.N. et al. [32] GerontoNet ADR Risk Score 
Alassaad A. et al. [33] The 80+ score 
Suggett E. [34] Risk scores to identify  
patients who were at high risk of 
(hospital) pharmacist intervention (no specific 
name for score stated by authors) 
Hohl C.M. et al. (2017) [35] Clinical decision rules 
Hohl C.M. et al. (2012) [20] Clinical decision rules 
Bonnerup D.K. et al. [36] MERIS score 
Kaufmann C.P. et al. (2018) [37] Drug-Associated Risk Tool (DART) 
Falconer N. et al. (2014) [38] Assessment of Risk Tool (ART) 
Falconer N. et al. (2017) [39] Assessment of Risk Tool (ART), 
McAuliffe L. et al. [40] MEDCOINS score 
McElnay J.C. et al. [41] A predictive model for adverse drug 
events (ADEs) in elderly patients (no specific 
name for model stated by authors) 
Urbina O. et al. [3] A score that quantifies the risk of a DRP 
during hospital admission (no specific name for 
score stated by authors) 
Hickson R.P. et al. [18] Pharmaceutical assessment screening tool 
(PAST) 
Saedder E.A. et al. [42] MERIS score 
Petrovic M. et al. [43] GerontoNet ADR Risk Score 
O’Mahony D. et al. [44] The adverse drug reaction risk in older 
persons (ADRROP) prediction scale 
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3.1. Included Papers 
Full details of the data extracted from the included studies are included in the Supporting 
Information, Table S1. 
3.2. Population Characteristics: Age 
All of the studies were conducted in the hospital setting and, as per inclusion criteria, in adult 
patients. Seven of the studies were carried out exclusively in elderly patients (aged 65 years and over) 
[25,30–32,41,43,44] and only the very elderly (aged 80 years and over) were represented in a further 
study [33]. Two studies [18,38] did not report the age demographics of the study participants 
(although participants were adults). The remaining studies were conducted in adult patients 
(including but not exclusively elderly patients) [3,20,34–37,39,40,42]. The majority of the studies 
presented either the mean or median age for participants, with the mean age of participants varying 
from 51.4 years [20] to 86.7 years [33], showing significant variations between the participants of the 
various studies. 
3.3. Population Characteristics: Gender 
There were significant differences in the gender profiles for participants in the differing studies, 
with four studies [18,30,38,42] not reporting this characteristic; in the remaining fifteen studies, 
female participants represented 46%–72% of the sample populations, so there were significant 
differences between the study populations with regard to this, with differences also observed 
between those included in the development and individual validation studies carried out by the same 
researchers, e.g., females accounted for 49% of participants in the first validation study conducted by 
Kaufmann et al. in 2018, compared to 61% of participants in the second validation study after the 
questionnaire was revised[37]. 
3.4. Population Characteristics: Ethnicity 
Ethnicity was only reported in two of the studies [25,38], with 88% white-British ethnicity 
reported in one study [38] and 51.1% European, 23% Pacific Island decent, Maori and 13.6% ‘others’ 
(25) in the second study. 
The other study was conducted in New Zealand and the population that the hospital served was 
described as being “an ethnically diverse population largely consisting of people of Maori and Pacific 
descent, with a high proportion of the population living in the most socio-economically deprived 
communities” [38]. This highlights significant differences between the populations where the two 
studies that reported participant ethnicity were conducted (Brighton, UK compared to New Zealand). 
3.5. Population Characteristics: Number of Study Participants 
The number of participants included in each study varied significantly from 35 patients [18] to 
10,807 [35].  
3.6. Development/Modelling, Utilisation or Validation of Assessment Tools 
Different studies examined the development/modelling, utilisation or validation of an 
assessment tool and combinations of these phases. Validation of the majority of studies was internal, 
whilst four provided external validation [20,30,32,43], and one of these studies included both internal 
and external validation [25]. The majority of studies used separate populations to develop and 
subsequently validate their tools, whilst two studies [31,33] used the same populations and used 
bootstrapping techniques to test the developed tool and a third used internal cross validation 
methods [40]. Overall, nine of the studies involved the development (or adaptation of a draft version 
of a tool) and internal validation of the assessment tool [3,18,31,34,40–42,44]. One study involved the 
development and external validation of a tool [30], whilst another involved the development, internal 
and external validation of a tool [25]. One study [20] only described the development of an assessment 
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tool (which was subsequently utilised in a further study; see below [35]); another study described the 
development and subsequent utilisation (rather than validation) of a tool [38], four studies described 
the utilisation or internal validation of a previously developed tool [35–37,39], and two studies 
provided external validation (only) of the previously developed GerontoNet ADR Risk Score [32,43]. 
3.7. Study Setting (Country/Countries) 
The majority of the studies (74%) were conducted in European centres [3,18,25,30–34,36,37,41–
44], and the remaining studies were conducted in New Zealand [38,39], Canada [20,35] and the US 
[40]. In two of the European-based studies [25,30], the development phase took place in Europe and 
the developed tools were then externally validated within centres in four European countries (and 
also internally validated in one of the studies [25]). The GerontoNet ADR Risk Score was developed 
and externally validated in Europe [30] and subsequently externally validated in two further 
European studies [32,43]. 
3.8. Primary Outcomes of the Studies 
The primary outcomes for the studies varied significantly. Five studies assessed the incidence 
(or rate) of ADRs [25,30,32,43,44] and another three studies looked at the incidence (or rate) of ADEs 
[20,31,41]. There were also subtle differences between studies with the same broad primary outcomes 
with respect to definitions/interpretations—for example, one study looked at the incidence of “non-
trivial ADRs” [44] and another specified that their primary outcomes were ADEs that required a 
change in medical therapy, diagnostic testing, consultation, or hospital admission [20]. The primary 
outcomes for the remaining studies were more specific/individual to each study and included the 
incidence of medication errors per patient [42], prescribing errors (PEs)[36], medication discrepancies 
on medication reconciliation at admission and Pes [39], time to rehospitalisation or death during the 
year following discharge [33], the number of DRPs per admission [3], the rate of potentially avoidable 
hospital readmission at 30 days [40] and the rate of pharmacist interventions [34]. These variations in 
the primary outcomes (and even differences in the exact definitions included within these primary 
outcomes) made it difficult to compare or collate the results and findings of the different studies, as 
they were not measuring the same parameters.  
3.9. Number of Risk Factors Included in Risk Scores/Tools 
The number of risk factors identified by and included in the risk scores/tools ranged from three 
[36,40,42] to thirty eight [38]. One study described the development of two clinical decision rules 
(CDRs) containing seven and four risk factors respectively [20]; in a subsequent study by the same 
researchers, a modified ADE CDR was used which was composed of five risk factors [35]. One study 
identified thirty eight flags for inclusion as part of an Assessment Risk Tool (ART) [38]; in the 
subsequent validation study reported in 2017, twenty five of these ART flags were included—four of 
which were found to be significantly associated with at least one unintentional medication 
discrepancy [39]. 
3.10. Identification of Risk Factors 
The risk factors included in the various studies and tools/scores were identified via a number of 
methods—these included clinical judgement, from literature review (alone), patient 
characteristics/variables and by combinations of methods. For example, one study identified possible 
risk factors from available study data (demographic and clinical details) and previously established 
risk factors from published reports [44]. In another study, five consecutive steps (literature search, 
Delphi process, construction of algorithm, calibration of algorithm, and prospective pilot study) were 
used to develop the algorithm [42]. 
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3.11. Statistical Analysis 
Statistical analysis was conducted and reported to determine the performance of the various 
tools/models in seventeen of the nineteen studies [3,18,20,25,30–34,36,37,39–44], but there was 
variation in the extent and types of statistical analyses conducted. In the other two studies [35,38], the 
development of a tool was described but validation of the tool was not conducted (38); statistical 
analysis was conducted to determine the value of medication review by pharmacists of patients 
identified by the CDR but not to evaluate the performance of the CDR itself [35]. 
3.12. Methodologies for Development of Point Scores 
Different methods were used in the various studies to develop the point scores for the 
tools/models described. In 15 of the studies, the methodology described the weighting system used 
for the different variables included in the scores—of which, 14 were individualised for the different 
variables [3,30–34,36,38–44], whilst one assigned arbitrary weighting to the variables [25]. Four of the 
14 studies with individualised weighting were based on theoretical weighting [36,42] or determined 
via group consensus [38,39]; the exact methodology used for determining weighting was unclear in 
one study [41] (although odds ratios and beta coefficients were calculated and included in the write 
up). In the remaining nine (of the 14) studies, the methodologies described the calculation and use of 
odds ratios, beta coefficients and regression coefficients to determine weightings of individual 
variables. Four studies did not report on the calculation of weightings of variables in risk scores; in 
one study, no score was calculated [37], whilst the levels of risk were assigned by meeting set criteria 
for following an algorithm in the remaining three studies [18,20,35]. 
3.13. Performance of Risk Score/Tool/Model: Sensitivity, Specificity and/or Discriminatory Ability 
The majority of the studies reported on the sensitivity, specificity and/or discriminatory ability 
of the risk score/tool/model. Sensitivity and specificity were reported in six of the studies 
[20,25,30,37,41,42], and discriminatory ability (including AUC/AUROC/AUCROC, C-statistics) or 
overall accuracy was reported in thirteen of the studies [3,25,30–34,39–44] including four studies, 
where sensitivity, specificity and discriminatory ability were all reported [25,30,41,42]. There were 
four studies which did not report sensitivity, specificity or discriminatory ability/overall accuracy of 
the scores/tools [18,35,36,38]. These results are summarised in Table 2.
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Table 2. Table showing the reported sensitivity, specificity, discriminatory ability and overall accuracy of the risk scores/tools used in each study. 
Author Sensitivity Specificity 
Other 
Discriminatory Ability: 
AUROC/AUCROC 
Discriminatory 
Ability: C-Statistic 
Overall 
Accuracy Other 
Tangiisuran B. et al. 
80.0% for internal 
validation; 84% for 
external validation 
55.0% for internal 
validation; 43% for 
external validation 
0.74 (95%CI = 0.68–0.79) for internal 
validation; 0.73 (95%CI = 0.66–0.80) for 
external validation 
      
Onder et al. 68% (development) 65% (development) 
0.71 (95% CI = 0.68–0.73) (development)  
0.70 (95% CI = 0.63–0.78) (validation) 
      
Trivalle et al. n/r n/r 0.70 (95% CI = 0.635–0.74)       
O'Connor et al. n/r n/r 
0.62 (95% CI = 0.57–0.68) on admission  
(lower on subsequent days,  
days 5 & 10 post-admission) 
      
Alassaad A. (&et al) n/r n/r   0.71     
Suggett E. n/r n/r 
0.607 for main data; 0.616 for validation 
data 
      
Hohl et al (2017) n/r n/r n/r n/r n/r   
Hohl et al (2012) 
1) More sensitive rule 
(ADE rule) 96.7% 
(95%CI = 91.8–98.6%) 
1) 40.3%         
2) More specific rule 
(Adverse Drug 
Reaction Rule) 90.8% 
(95%CI = 81.4–95.7%) 
2) 59.1%         
Bonnerup et al. n/r n/r n/r n/r n/r   
Kaufmann et al. 
67% average (range = 
21–100) 
88% average (range = 
27–100) 
n/r       
Falconer et al. (2014) n/r n/r n/r n/r n/r   
Falconer et al. (2017) n/r n/r 
0.72 (95%CI = 0.66–0.78) to predict at least 
one unintended medication discrepancy; 
from score from 2 flags (>8 regular 
admission medicines and readmission 
within 30 days of discharge) 
      
McAuliffe et al. n/r n/r   
0.65 (95%CI = 0.60–
0.70) 
  
Hosmer-
Lemeshow 
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goodness-of-fit 
= 0.99 
McElnay et al. 41% (validation) 69% (validation)     63%   
Urbina et al. n/r n/r 
0.778 (95% CI = 0.768–0.789) (training set); 
0.776 (95%CI = 0.759–0.792) (validation 
set) 
    
Hosmer-
Lemeshow 
goodness-of-fit 
= non-
significant (p = 
0.13) 
(validation set) 
Hickson et al. n/r n/r n/r n/r n/r n/r 
Saedder et al. 
0.64 (for final version 
of MERIS) 
0.75 (for final version 
of MERIS) 
0.76, 0.87, 0.74, 0.66 for final MERIS score 
in different populations within study 
      
Petrovic et al. n/r n/r 
0.64 (95%CI = 0.55–0.74) to predict ADRs 
probably or definitely related to drug use; 
0.69 (95%CI = 0.60–0.77) for predicting 
Type A ADRs; subgroup analysis: AUC = 
0.70–0.79 and 0.80–0.89 
      
O'Mahony et al. n/r n/r 
0.623 (95% CI = 0.598–0.665) (derivation 
cohort); 0.592 (95%CI = 0.532–0.652) 
(vallidation cohort) 
      
n/r = not relevant. 
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3.14. Sample Size and Power of Study 
The events per variable (EPV) ratio is often used to assess the adequacy of the sample size when 
developing a risk model. The EPV ratio “is calculated by using the number of outcomes divided by 
the number of candidate predictor variables in the development cohort” and a minimum EPV ratio 
of 10 is usually recommended {28]. The results show that only two studies had adequate sample sizes 
using the EPV ratio>10 rule [3,30]. The remaining studies that involved the development of a risk 
model/tool either did not contain an adequate sample size [25,33] or the details were unclear or not 
reported in these studies. In the case of one study [38], the tool consisting of 38 variables or risk factors 
was developed from consensus opinion rather than modelling methods and so the EPV ratio was 
regarded as not applicable in this instance. 
In the validation studies, only four studies [3,32,35,39] were sufficiently powered (with >100 
events), and the remaining validation studies were either underpowered or there was not sufficient 
information to accurately assess this parameter [28]. 
3.15. Quality of Included Studies 
Six (32%) of the included studies described how missing data were handled [20,25,35,37,40,43]. 
In the remaining studies, it was either unclear or not reported how missing data were handled. From 
the papers describing the studies, study outcomes were assessed blinded in six studies 
[18,20,35,36,39,42]. It was either unclear or not reported whether study outcomes were assessed 
blinded in the remaining studies. Only two of the studies [3,30] that included the development of a 
tool using modelling methods (excluding, for example, the development of a tool by consensus 
methods rather than modelling [18]) reported a sufficient sample size using the “rule of thumb” of 
the EPV ratio>10 that is commonly adhered to by researchers when developing prediction tools [28]. 
In the validation studies or those studies with a separate validation arm, only four [3,32,35,39] 
reported a sufficient event rate to suggest that the (validation) study was adequately powered (with 
>100 events reported). In the remaining studies, the sample size or powering was either insufficient 
or not clearly reported.  
4. Discussion 
The population characteristics, methodologies, primary outcomes and presentation of results of 
the nineteen studies included in this SR vary significantly, making quantitative synthesis of their 
findings and meta-analysis unsuitable for this review. Instead, narrative synthesis of the findings was 
conducted and presented. 
The results of this SR do not currently support the use of any of the models identified in routine 
clinical practice, similar to the findings of a previous SR [7]. Only four of the nineteen studies included 
any external validation [25,30,32,43]. External validation would provide confidence that a particular 
model’s predictive ability is reliable across different populations and settings. Even in the four studies 
which incorporated external validation, there were limitations to usefulness of the models/scores 
involved as outlined below  
The sensitivity of a predictive model measures the ability of the model to correctly predict 
(identify) individuals who will experience the outcome (e.g., who have an ADR) (true positive), 
whilst specificity is a measure of the true negative rate of the model, measuring the ability of the 
model to correctly predict those individuals who will not experience the outcome (e.g., an ADR). 
Whilst a satisfactory level of sensitivity of 80% was reported for the BADRI model, its low specificity 
of 46% meant that “the model may incorrectly label patients ‘at risk of an ADR’ who will not 
ordinarily go on to experience such an event”[25].  
The GerontoNet ADR Risk Score (developed by Onder et al.) showed comparable discriminatory 
ability to the BADRI model (with AUROC of 0.71 in the development phase for the GerontoNet ADR 
Risk Score and 0.74 for internal validation of the BADRI model) but the sensitivity for the GerontoNet 
ADR Risk Score was lower than that for the BADRI model (68% and 80% respectively); the specificity 
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of both models was low but the specificity was higher for the GerontoNet ADR Risk Score (at 65%) 
compared to the BADRI model (at 55%)[25,30]. 
External validation of the GerontoNet ADR Risk Score [32] identified an AUC value of 0.62 (on 
admission) and also reported that the score incorrectly classified 38% of patients as being at low risk 
of ADRs [32], showing poor performance of the score [43]. 
A second published external validation for the GerontoNet ADR Risk Score [43] reported that 
AUC values of 0.64 and 0.69 were calculated to predict (1) ADRs probably or definitely related to 
drug use and (2) type A ADRs (type A (intrinsic) reactions are those that are usually predictable from 
the known pharmacology of a drug), respectively. From the researchers’ own definitions of model 
performance, these AUC values show poor performance of the GerontoNet ADR Risk Score. In 
particular in subpopulations of older hospitalised patients, the GerontoNet ADR Risk Score was 
found to have fair to good diagnostic accuracy, with AUC values of 0.70–0.79 and 0.80–0.89. It was 
concluded that the GerontoNet ADR Risk Score could be adopted for use in older patients belonging 
to the specific subpopulations; these findings suggest that the GerontoNet ADR Risk Score may not 
be suitable for routine clinical use in the general elderly (65 years and over) hospital in-patient 
population for which it was originally developed [43]. 
4.1. Limitations 
There are a number of possible limitations to this SR. The search strategy used to identify 
relevant studies included “pharmacist” as an essential search term. Whilst this was deemed 
appropriate, as the focus of the SR was prioritising patients for pharmacist review, it is possible that 
other research that identified risk prediction models for elderly patients experiencing DRPs could 
have been excluded if they did not include a pharmacist in the study methodology; such studies may 
have provided useful insight into factors and models to predict the likelihood of DRPs in elderly in-
patients. To minimise the potential for “missing” relevant studies, the PICOS framework was used 
to formulate the search strategy, and all three researchers extensively discussed the choice of search 
terms to be used. Due to the heterogenous nature of the methodologies and patient demographics, 
the outcomes and reporting of results, it was not possible to conduct a meta-analysis and instead a 
qualitative analysis was conducted. However, the CHARMS checklist was used to try to 
systematically assess the quality of the included studies and minimise subjectivity. It is recognised 
that it was difficult to assess bias due to the relatively small number of studies (insufficient), 
heterogeneity and the lack of preregistered protocols [45]. 
5. Conclusions 
The findings from this systematic review show that a number of tools have been developed for 
use in the (acute) hospital setting for assessment of the risk of older people experiencing drug-related 
problems, including ADRs and AEs. The tools developed to date vary in their complexity, outcome 
measures and how their performance has been validated. There is no definitive validated assessment 
tool which is in widespread use for this group of patients. None of the tools identified in this SR 
“satisfied the four key stages in the creation of a quality risk prediction model” (7)—development, 
validation, impact and implementation. Whilst research to date has focused on the development and 
validation of such tools, further work is needed to assess the potential impact of utilising the tools 
and their implementation.  
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